Evidence map›Paper›PMID 40993146›Full record

Trial reportNature communications2025

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.

Xiuning Le, Jacqulyne P Robichaux, Monique Nilsson, R S K Vijayan, Ashwin Ravichandran, Jia Wu, Yasir Y Elamin, Lingzhi Hong, Jun Pei, Jun He and 16 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8554-1185
Jacqulyne P RobichauxDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8812-7054
Monique NilssonDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
R S K VijayanInstitute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA.
Ashwin RavichandranKBR Inc., Intelligent Systems Division, NASA Ames Research Center, Moffett Field, Mountain View, California, USA.
Jia WuDepartment of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8392-8338
Yasir Y ElaminDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5312-909X
Lingzhi HongDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6553-3279
Jun PeiInstitute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA.
Jun HeDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Sonia PatelDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Hibiki UdagawaDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Sriramvignesh ManiDepartment of Chemistry, The University of Chicago, Chicago, Illinois, USA.
Chang Woon JangKBR Inc., Intelligent Systems Division, NASA Ames Research Center, Moffett Field, Mountain View, California, USA.
Jeffrey M ClarkeMedical Oncology, Duke University Medical Center, Durham, NC, USA.
Nishan TchekmedyianMedical Oncology, City of Hope, Irvine, CA, USA.
Jonathan W GoldmanDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-4925-8243
Mark SocinskiAdventHealth Cancer Institute, Orlando, Florida, USA.
Gajanan BhatSpectrum Pharmaceuticals, Henderson, NV, USA.
Sharon LeuSpectrum Pharmaceuticals, Henderson, NV, USA.
Veronica BunnTakeda Pharmaceutical Company, Cambridge, MA, USA.
Zhenqiang SuTakeda Pharmaceutical Company, Cambridge, MA, USA.
Sylvie VincentTakeda Pharmaceutical Company, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7247-2467
John W LawsonIntelligent Systems Division, NASA Ames Research Center, Moffett Field, Mountain View, California, USA.
Jason B CrossInstitute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. jheymach@mdanderson.org.ORCID http://orcid.org/0000-0001-9068-8942

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
University of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAMODARAN, SENTHILKUMAR, MERIC-BERNSTAM, FUNDA · 2017 to 2022
$7.7M
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitorsR01CA247975 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., JONES, PHILIP · 2020 to 2024
$2.8M
Therapeutic strategies against EGFR exon 20 mutant lung cancerR01CA234183 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2020 to 2024
$2.8M
Overcoming Resistance to Anti-EGFR Therapy by Drug RepurposingR01CA190628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG, HEYMACH, JOHN V. · 2015 to 2019
$2.6M
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)R50CA265307 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NILSSON, MONIQUE B · 2021 to 2025
$585k
NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA190628NCI NIH HHS R01 CA234183NCI NIH HHS R01 CA247975NCI NIH HHS R50 CA265307NCI NIH HHS U54 CA224065
6 · The paper itself

Abstract

EGFRex20 insertions (EGFRex20ins) can be classified as near- and far-loop based on the insertion location, however, the impact of location on responses to various EGFR tyrosine kinase inhibitors (TKIs) is poorly understood. In vitro studies show that afatinib, poziotinib, and zipalertinib more potently inhibited near-loop than far-loop insertions, whereas mobocertinib has similar IC

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPiperazinesProtein Kinase InhibitorsPyrimidinesQuinazolinesAdultAgedErbB ReceptorsExonsFemaleHumansMaleMiddle AgedMolecular Dynamics SimulationMutagenesis, InsertionalEGFR protein, humanErbB ReceptorsHM781-36BPiperazinesProtein Kinase InhibitorsPyrimidinesQuinazolines

Identifiers

PMID40993146
PMCPMC12460621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.